相关实验视频

Updated: Feb 27, 2026

Cell-Free DNA Integrity Analysis in Urine Samples

Cell-Free DNA Integrity Analysis in Urine Samples

Published on: January 5, 2017

CD36 rs1761667 多态性及其对膀癌分子特征的影响

Mihai Ioan Pavalean^1,2, Ioana Maria Lambrescu^1,3, Gisela Gaina^1,3

¹Department of Morphological Sciences, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.

Diseases (Basel, Switzerland)

|February 26, 2026

概括

CD36中的遗传变异可能会影响膀癌风险. rs1761667变种与膀癌患者的CD36mRNA表达改变有关,这表明它可能在疾病途径中发挥作用.

科学领域:

遗传学是一个遗传学.
在瘤学瘤学.
分子生物学分子生物学

背景情况:

膀癌是一种复杂的疾病,具有新兴的遗传联系.
CD36是一种拾尸体受体,参与脂质代谢和瘤进展.
CD36基因变异在膀癌中的作用尚未被探索.

研究的目的:

为了研究rs1761667单核酸多态和CD36mRNA表达水平之间的关联.
探索CD36基因变异对膀癌发病的潜在影响.

主要方法:

在30名膀癌患者和19名对照中使用PCR-RFLP对rs1761667变异的基因定型.
通过RT-qPCR对CD36mRNA表达的量化.
使用2^-ΔΔCt方法对基因型表达相关性的统计分析.

主要成果:

在膀癌患者的rs1761667基因型中,CD36 mRNA表达显著不同.
与GG携带者相比,AA基因型携带者表现出较低的CD36表达 (p=0.03).
在对照组中没有发现显著的基因型依赖表达差异,基因型分布在病例和对照组之间没有差异.

结论:

在膀癌的背景下,rs1761667变异可能以基因型依赖的方式影响CD36转录.
这些发现表明,遗传CD36变异与膀癌相关的生物学途径之间存在潜在的联系.
进一步验证瘤组织是有必要的,以证实这些结果.

关键词:

这就是CD36基因.膀癌:膀癌是一种癌症.遗传变异是一种遗传变异.rs1761667 多形态的多态性瘤等级是瘤等级的

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...